US COVID Vaccine Authorizations: Too Much – Or Never Enough?

17 Jun 2022

• By Michael McCaughan

A US FDA advisory committee review of a novel COVID vaccine candidate from Novavax made one thing very clear: The agency is firmly convinced that when it comes to vaccine options, more is better.

Novavax syringe — • Source: Shutterstock

National media attention is understandably focused on the US Food & Drug Administration’s public review of data to expand use of COVID vaccines into the youngest pediatric populations.

The attention given to the two-day meeting of the Vaccines & Related Biological Products Advisory Committee considering data for